Results 111 to 120 of about 11,599 (234)

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou   +10 more
wiley   +1 more source

Mutagenecity of enniatin a1 and b1 mycotoxins in ames salmonella microsome test [PDF]

open access: yesKafkas Universitesi Veteriner Fakültesi Dergisi, 2014
YILMAZ E
doaj   +1 more source

ATP13A2 is involved in intracellular polyamine transport in lung epithelial cells. [PDF]

open access: yesFEBS Open Bio
Hatori Y   +8 more
europepmc   +1 more source

Comments to the Article Wu Y, Völler S, Goulooze SC, et al. A Novel Maturation Equation for Hepatic Clearance Across Preterm, Term Neonates, Children, and Adults: Application to Paracetamol and Its Metabolite. J Clin Pharmacol. 2025;65(12):1829‐1843. doi: 10.1002/jcph.70080. PMID: 40910464; PMCID: PMC12649303

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract A recent article in this journal by Wu et al presented a comprehensive model for the maturation of paracetamol clearance from birth to adulthood using pooled plasma and urinary data of the parent drug and its metabolites from 298 subjects. The modeling showed that the oxidative bioactivation to hepatotoxic metabolite N‐acetyl‐p‐benzoquinone ...
Markku Pasanen, Risto O. Juvonen
wiley   +1 more source

Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post‐DAA Management

open access: yesJournal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Hepatitis C virus (HCV) infection remains a major global health burden despite advances in direct‐acting antiviral (DAA) therapies. Beyond hepatic complications such as cirrhosis and hepatocellular carcinoma (HCC), HCV has been strongly linked to metabolic disorders, particularly type 2 diabetes mellitus (T2DM).
Shen‐Shong Chang   +3 more
wiley   +1 more source

Hepatopulmonary syndrome as presentation of pediatric metabolic dysfunction‐associated steatohepatitis

open access: yesJPGN Reports, Volume 7, Issue 2, Page 362-365, May 2026.
Abstract Childhood obesity is rising and leading to serious co‐morbidities, among which is metabolic dysfunction‐associated steatotic liver disease (MASLD) predisposing individuals to cirrhosis. We describe a young 11‐year‐old Hispanic male who presented with hepatopulmonary syndrome secondary to cirrhotic portal hypertension from metabolic dysfunction‐
Shruti Sakhuja   +6 more
wiley   +1 more source

Eicosapentaenoic and Docosahexaenoic Acid Levels in Mouse Tissues After Intake of Echium and Ahiflower Oils Rich in Stearidonic and α‐Linolenic Acids

open access: yesLipids, Volume 61, Issue 3, Page 417-426, May 2026.
Dietary supplementation with stearidonic acid–rich Echium and Ahiflower oils increases EPA levels across multiple mouse tissues, while DHA responses remain tissue‐specific and limited, supporting the strategic use of plant‐based omega‐3 sources for EPA‐focused interventions. ABSTRACT Omega‐3 fatty acids (n‐3 FA), particularly eicosapentaenoic acid (EPA)
Letícia V. Segre   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy